SOX17 Recombinant Rabbit mAb (SDT-1803-48)

產(chǎn)品型號：S0B2361

更新時(shí)間：2025-10-11

廠商性質(zhì)：生產(chǎn)廠家

訪問量：161

服務(wù)熱線

15855403091

立即咨詢

產(chǎn)品分類

PRODUCT CLASSIFICATION

抗體/抗原

ELISA試劑盒抗體試劑盒二抗試劑盒二抗其它流式抗體瓊脂糖/磁珠偶聯(lián)抗體抗Payload抗體泛修飾抗體標(biāo)簽/內(nèi)參抗體功能性抗體 Biosimilar抗體偶聯(lián)抗體配對抗體病理/IHC抗體

查看全部產(chǎn)品

癌癥治療新紀(jì)元：ADC藥物如何以“精準(zhǔn)制導(dǎo)+超級彈頭“改寫抗癌規(guī)則？

成纖維細(xì)胞生長因子21：代謝調(diào)控的新星與治療前沿

GFAP Mouse mAb的應(yīng)用領(lǐng)域有哪些？

產(chǎn)品介紹

SOX17 protein, a member of the SOX （SRY-related HMG-box） family of transcription factors, is crucial for the regulation of embryonic development and cell fate determination. It plays a key role in endoderm development, cardiovascular system formation, maintenance of fetal hematopoietic stem cells, and postnatal angiogenesis. SOX17 also functions as a transcriptional regulator that binds to specific DNA sequences and modulates transcriptional regulation via WNT3A, inhibiting Wnt signaling and promoting the degradation of activated CTNNB1. Furthermore, it has been implicated in cancer, particularly as a mutated cancer driver gene in endometrial carcinoma, with missense mutations potentially converting SOX17 into a pluripotency-inducing factor and altering its DNA binding preferences and gene expression programs. SOX17 is also considered to act as a tumor suppressor through the attenuation of WNT/β-catenin signaling in various cancer types.

上一個(gè)：S0B1261Invivo human IgG1 isotype control